# A5401 COVID Supplement

> **NIH NIH UM1** · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2020 · $3,770,048

## Abstract

ABSTRACT
The AIDS Clinical Trials Group (ACTG) has been selected to lead a Master Adaptive protocol under the
Accelerating COVID-19 Therapeutic Interventions and Vaccine (ACTIV) Operation Warp Speed. This trial
(ACTG 5401 or ACTIV-2) will evaluate multiple monoclonal antibodies and other small molecules for outpatient
COVID treatment. The Laboratory Center will expand its efforts to include support for COVID-19 clinical trials.

## Key facts

- **NIH application ID:** 10203227
- **Project number:** 3UM1AI106701-07S1
- **Recipient organization:** UNIVERSITY OF CALIFORNIA LOS ANGELES
- **Principal Investigator:** Grace M Aldrovandi
- **Activity code:** UM1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $3,770,048
- **Award type:** 3
- **Project period:** 2020-07-09 → 2021-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10203227

## Citation

> US National Institutes of Health, RePORTER application 10203227, A5401 COVID Supplement (3UM1AI106701-07S1). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10203227. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*